[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350524-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350524-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","fibroblastic-aspartoacylase-suppresses-tgf-mediated-responses-and-cancer-progression","Fibroblastic aspartoacylase suppresses TGFβ-mediated responses and cancer progression","","Metabolic reprogramming is a hallmark of cancer, but its adaptation in stromal cells is less understood. This article identifies aspartoacylase (ASPA) as a metabolic enzyme repressed in tumor stroma and cancer-associated fibroblasts (CAFs), revealing reciprocal regulation with TGFβ signaling. TGFβ suppresses ASPA expression in fibroblasts, while ASPA restrains TGFβ-driven myofibroblast conversion, extracellular matrix remodeling, angiogenesis, and protumoral macrophage phenotypes. Human specimen analyses link low ASPA to worse prognosis across tumor types and to aggressive TGFβ-associated responses.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/fibroblastic-aspartoacylase-suppresses-tgf-mediated-responses-and-cancer-progression/350524/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/fibroblastic-aspartoacylase-suppresses-tgf-mediated-responses-and-cancer-progression/350524.png","ImageObject",300,407,{"name":42,"@type":43},"Kurz","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What metabolic enzyme is identified as repressed in tumor stroma and CAFs?","Question",{"text":63,"@type":64},"Aspartoacylase (ASPA) is identified as a metabolic enzyme consistently repressed in tumor stroma and cancer-associated fibroblasts (CAFs).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do ASPA and TGFβ signaling influence each other in fibroblasts?",{"text":68,"@type":64},"TGFβ suppresses ASPA expression in fibroblasts, while ASPA restrains TGFβ-dependent myofibroblast conversion and downstream tumor-promoting processes.",{"name":70,"@type":61,"acceptedAnswer":71},"What tumor-promoting outcomes are associated with TGFβ and reduced ASPA?",{"text":72,"@type":64},"Reduced ASPA is linked to stronger TGFβ-driven effects, including extracellular matrix remodeling, angiogenesis, and protumoral macrophage phenotypes, contributing to cancer progression.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350524,1790544636,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":33,"preview_urls":144},2336478945635,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article [https://doi.org/10.1038/s41467-026-73002-6](https://doi.org/10.1038/s41467-026-73002-6)  \nFibroblastic aspartoacylase suppresses TGFβ-mediated responses and cancer progression  \nReceived: 25 March 2024  \n\n| Accepted: 30 April 2026 |\n| --- |\n| |\n| Check for updates |\n\nIanire Astobiza 1,2,30, Catalina Capó-Serra3,30, Cristina Viera1,30,  \nJavier Rodríguez3, Patricia Carnicero 3, Miguel Juliá 3, Ainara Martinez1, Carmen Pérez-López3, María Subijana3, Carolina Ortiz-Sanz1,  \nSaioa Garcia-Longarte 1,2, Isabel Mendizabal 1,2,4,5, Emily J. Kay6,  \nCarla Riera-Domingo 7,8, Silvia Rivis7,8, Onintza Carlevaris1,  \nLeire Egia-Mendikute1, Sara Cascais9, Natalia Martín-Martín1,2,5,  \nSonia Fernandez-Ruiz1,2, Veronica Torrano 2,10, Jana R. Crespo1,  \nMikel Pujana-Vaquerizo1,2, Elisa Espinet 11,12, Andreas Trumpp 13,14,15, Noemi Eiro 16, Francisco J. Vizoso16, Ana Vivancos 17, Joan Seoane 17, David Gonzalo5,18, Soﬁa Rey18, Aida Santos-Martin18, Aitziber Ugalde-Olano2,5,19, Claudia Manini20,21, Jose I. Lopez22,23, Diana Cabrera1, Sebastian M. Van Liempd1, Juan M. Falcon-Perez 1,24, Roger R. Gomis 2,25,26, Asís Palazon 1,4, Christian Frezza 27, Mireia Castillo-Martin9, Sara Zanivan 6,28,29, Massimiliano Mazzone 7,8, Miguel Unda 2,5,18, Ana Loizaga-Iriarte2,5,18, Arkaitz Carracedo 1,2,4,5,10  & Fernando Calvo 3   \nMetabolic reprogramming is a hallmark of cancer, and the ﬁeld has predominantly focused on investigating metabolic alterations in tumour cells. However, the relevance, mechanism and consequences of metabolic adaptations in stromal cells remain understudied. Here, we identify aspartoacylase (ASPA) as a metabolic enzyme consistently repressed in tumour stroma and cancer-associated ﬁbroblasts (CAFs). Importantly, we report a reciprocal crosstalk between ASPA and Transforming Growth Factor Beta (TGFβ) signalling that inﬂuences ﬁbroblast behaviour. TGFβ suppressesASPA expression in ﬁbroblasts, whereas ASPA restrains TGFβ-dependent myoﬁbroblast conversion, extracelullar cell matrix (ECM) remodelling, angiogenesis and protumoral macrophage phenotypes. Analyses of human specimens revealed a strong negative prognostic value for ASPA in different tumour types, associated with TGFβ signalling levels and the generation of aggressive protumoral responses. Our ﬁndings unveil ASPA expression in ﬁbroblasts as agatekeeper of TGFβ responses and activation in cancer progression.  \nTumour cells exploit diverse metabolic strategies to support uncontrolled proliferation, resist cell death, and adapt to ﬂuctuating nutrient and oxygen availability1. Traditionally, studies have focused on cancer cell-autonomous metabolic alterations that support tumour  \npathogenesis, progression and resistance to therapy1,2. However, tumours are not composed of cancer cells in isolation. Instead, they function as complex ecosystems in which malignant, stromal, and immune cells engage in dynamic and reciprocal interactions that  \nA full list of afﬁliations appears at the end of the paper. e-mail: [acarracedo@cicbiogune.es](acarracedo@cicbiogune.es); [calvof@unican.es](calvof@unican.es)  \ninﬂuence tumour characteristics3. Within this heterogeneous microenvironment, nutrient availability, waste accumulation, and metabolic by-products shape not only the behaviour of malignant cells, but also impact tumour microenvironment (TME) components and the overall trajectory of the disease4,5. However, how metabolic alterations shape the behaviour of stromal cells is not well understood.  \nAmong the various stromal components of the TME, cancerassociated ﬁbroblasts (CAFs) represent a predominant and functionally versatile population that plays a central role in supporting tumour growth, remodelling the extracellular matrix (ECM), regulating angiogenesis, and modulating immune responses6. CAFs do not represent a uniform cell type, but rather encompass a spectrum of phenotypic states that arise in response to contextual cues such as TGFβ, interleukin-1 (IL-1), hypoxia, and mechanic","cbCaigEKTZ5T5xin","https://ap.wps.com/l/cbCaigEKTZ5T5xin","pdf",6193318,"English","# Background\n## Metabolic strategies in cancer and the tumor microenvironment\n## Role and diversity of cancer-associated fibroblasts (CAFs)\n# ASPA in cancer biology\n## Known function of ASPA and emerging links\n## ASPA expression in tumor stroma and CAFs\n# ASPA–TGFβ crosstalk and functional outcomes\n## Effects on fibroblast activation and tumor-supporting phenotypes\n# Prognostic relevance\n## ASPA as a negative prognostic marker","[{\"question\":\"What metabolic enzyme is identified as repressed in tumor stroma and CAFs?\",\"answer\":\"Aspartoacylase (ASPA) is identified as a metabolic enzyme consistently repressed in tumor stroma and cancer-associated fibroblasts (CAFs).\"},{\"question\":\"How do ASPA and TGFβ signaling influence each other in fibroblasts?\",\"answer\":\"TGFβ suppresses ASPA expression in fibroblasts, while ASPA restrains TGFβ-dependent myofibroblast conversion and downstream tumor-promoting processes.\"},{\"question\":\"What tumor-promoting outcomes are associated with TGFβ and reduced ASPA?\",\"answer\":\"Reduced ASPA is linked to stronger TGFβ-driven effects, including extracellular matrix remodeling, angiogenesis, and protumoral macrophage phenotypes, contributing to cancer progression.\"}]","Fibroblastic aspartoacylase suppresses TGFβ-mediated responses and cancer progression | PDF",1790089413,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e2cb287ebee22cf4b1e87b3e57363093.webp",983,1305,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6bbfedf96da5dd48f1282dd5b348bd09.webp",982,1304,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ded9a156be273cb526cb30dd1bbff50e.webp",981,1303,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f163720d65e9d4421ef4ed701506b0d8.webp",980,1301]